生命科学资讯
生物技术与制药领域的最新动态
Ultragenyx unwraps data that may be central to its gene therapy resubmission
Pfizer takes $4.4B charge related to cancer drug in fourth-quarter earnings
Pfizer’s Metsera-originated monthly GLP-1 cuts weight by 10.5% at six months
AstraZeneca gets CRL for prefilled pen version of lupus drug Saphnelo
Carbon Health申请破产，寻求出售或重组。
Carbon Health files for bankruptcy, seeking to sell or restructure
首批10种医保谈判药品价格已生效：老年人真的省钱了吗？
First 10 Medicare-negotiated drug prices have taken effect: Are seniors really saving money?
新CagriSema数据显示优于司美格鲁肽的改善效果。
New CagriSema data show improvement over semaglutide
葛兰素史克将Wave的AATD RNA编辑项目权利归还。
GSK returns rights to Wave's RNA editing program for AATD
Spring Health收购Alma，拓展虚拟心理健康保险覆盖范围
Spring Health acquires Alma, expanding insurance reach in virtual mental health
协和麒麟临床试验揭示副作用；葛兰素史克成RAPT唯一竞购者。
Kyowa Kirin reveals side effect in trial; GSK was lone bidder for RAPT
FDA因包装问题拒绝批准Aquestive的抗过敏药物。
FDA rejects Aquestive's allergy drug over packaging issues
FDA开放PreCheck项目申请，加速美国工厂建设审批流程。
FDA opens submissions for PreCheck program to speed up US factory builds
赛诺根生物以2亿美元首付款将RNAi候选药物授权给基因泰克。
SanegeneBio licenses RNAi candidate to Genentech for $200M upfront
Pharming公司免疫缺陷药物获CRL，不适用于年轻患者。
Pharming’s immunodeficiency drug gets CRL for use in younger patients
欧洲法律变更意味着制药商可能更早面临仿制药竞争
European law changes mean drugmakers may have to grapple with generic competition sooner
大型药企财报季拉开序幕；第三轮IRA药品名单出炉；恒瑞医药迎来突破性时刻；更多行业动态。
Big Pharma earnings kick off; Third-round IRA drugs selected; Hengrui’s trailblazing moment; and more
FDA称已就Corcept被拒库欣综合征药物问题早期做出解释。
FDA says it explained issues early on for Corcept's rejected Cushing's syndrome drug
Bitterroot回归临床前生物技术领域，专注CD47靶点，同时CEO离职。
Bitterroot reverts to preclinical biotech in CD47 as CEO leaves
欧洲药品管理局人用药品委员会反对礼来Mounjaro用于心衰治疗，支持诺和诺德Kayshild。
CHMP opposes Lilly’s Mounjaro in heart failure, backs Novo’s Kayshild